跳至主要内容
临床试验/NCT01179152
NCT01179152Unknown不适用

Childhood Asthma and Return to School: the September Epidemic Exacerbation in Israel.A Controlled Trial of the Effectiveness of Preventive Treatment With Symbicort or Budicort Turbuhaler

Meir Medical Center1 个研究点 分布在 1 个国家目标入组 225 人开始时间: 2010年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
225
试验地点
1
主要终点
reduction of asthma exacerbation during the study period

研究概览

简要总结

During the second week of September( week 38 of the year)there are recorded data of exacerbation of asthma all over the world, including Israel. A short preventive treatment of 6 weeks may reduce asthma exacerbation in children,reduce primary care and ER visiting and hospitalization.

详细描述

During the second week of September( week 38 of the year)there are recorded data of exacerbation of asthma all over the world, including Israel. A short preventive treatment of 6 weeks may reduce asthma exacerbation in children,reduce primary care and ER visiting and hospitalization.

We will study the effectiveness of Budicort or Symbicort turbuhaler as a preventive treatment in children aged 6-18 years.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
6 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • age : 6-18 years suffering from asthma asthma exacerbation during 1/9/2009-15/10/2009

排除标准

  • any chronic condition that can involve respiratory tract (other than asthma) treated as prevention with ICS or montelukast from July 2010 Treated with oral steroids during the August 2010 asthma exacerbation one week prior study inclusion

研究组 & 干预措施

Budicort

Active Comparator

75 children will receive treatment with Budicort 200 mcg

干预措施: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler (Drug)

Symbicort

Active Comparator

75 children will receive treatment with Symbicort 160 mcg

干预措施: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler (Drug)

counselling

No Intervention

75 children who will not treated as their request but will be folowedup

干预措施: Budesonide turbuhaler, Budesonide+Formoterol turbuhaler (Drug)

结局指标

主要结局

reduction of asthma exacerbation during the study period

时间窗: An average time of 8 weeks

less asthma exacerbation

次要结局

  • less primary care physician visits(An average time of 8 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验